

# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSENDER FOR PATENTS PO Box 1430 Alexandria, Virginia 22313-1450 www.wopto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/644,703	08/19/2003	Louis A. Pena	30817-1008-CIP	7990
5170 03/07/2008 PEACOCK MYERS, P.C. 201 THIRD STREET, N.W.			EXAMINER	
			DANG, IAN D	
SUITE 1340 ALBUOUERO	QUE, NM 87102		ART UNIT	PAPER NUMBER
			1647	
			MAIL DATE	DELIVERY MODE
			03/07/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

## Application No. Applicant(s) 10/644,703 PENA ET AL. Office Action Summary Examiner Art Unit IAN DANG 1647 -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS. WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status 1) Responsive to communication(s) filed on 14 December 2007. 2a) This action is FINAL. 2b) This action is non-final. 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213. Disposition of Claims 4) Claim(s) 8.9.12-20.32 and 34-38 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration. 5) Claim(s) \_\_\_\_\_ is/are allowed. 6) Claim(s) \_\_\_\_\_ is/are rejected 7) Claim(s) is/are objected to. 8) Claim(s) 8.9.12-20.32 and 34-38 are subject to restriction and/or election requirement. Application Papers 9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are; a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abevance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. Priority under 35 U.S.C. § 119 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some \* c) None of: Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). \* See the attached detailed Office action for a list of the certified copies not received. Attachment(s) 1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413)

Notice of Draftsperson's Patent Drawing Review (PTO-948)

information Disclosure Statement(s) (PTO/S5/06)
 Paper No(s)/Mail Date \_\_\_\_\_\_.

Paper No(s)/Mail Date.

6) Other:

5) Notice of Informal Patent Application

Application/Control Number: 10/644,703 Page 2

Art Unit: 1647

#### DETAILED ACTION

### Status of Application, Amendments and/or Claims

The amendment of 14 December 2007 has been entered in full. Claims 10-11, 27-31,

33, 39-45 have been cancelled and claims 8, 12-15, 19, 20, 32, 34-37 have been amended.

Claims 8, 9, 12-20, 32, 34-38 are pending.

#### Election/Restrictions

The Examiner has determined that a further restriction is required.

Restriction to one of the following inventions is also required under 35 U.S.C. 121:

- A. A synthetic heparin binding growth factor analogue of SEQ ID NO: 6
- B. A synthetic heparin binding growth factor analogue of SEQ ID NO: 7
- C. A synthetic heparin binding growth factor analogue of SEQ ID NO: 8
- D. A synthetic heparin binding growth factor analogue of SEQ ID NO: 9
- E. A synthetic heparin binding growth factor analogue of SEQ ID NO: 10
- F. A synthetic heparin binding growth factor analogue of SEQ ID NO: 11
- G. A synthetic heparin binding growth factor analogue of SEQ ID NO: 12
- H. A synthetic heparin binding growth factor analogue of SEQ ID NO: 13
- A synthetic heparin binding growth factor analogue of SEQ ID NO: 14
- J. A synthetic heparin binding growth factor analogue of SEQ ID NO: 15
- K. A synthetic heparin binding growth factor analogue of SEQ ID NO: 16
- L. A synthetic heparin binding growth factor analogue of SEQ ID NO: 17
- M. A synthetic heparin binding growth factor analogue of SEQ ID NO: 16
- N. A synthetic heparin binding growth factor analogue of SEQ ID NO: 19

Application/Control Number: 10/644,703 Page 3

Art Unit: 1647

O. A synthetic heparin binding growth factor analogue of SEQ ID NO: 20

P. A synthetic heparin binding growth factor analogue of SEQ ID NO: 21

The inventions are distinct, each from the other because of the following reasons:

(1) the inventions as claimed are either not capable of use together or can have a materially

Inventions A-P are directed to related products. The related inventions are distinct if the

different design, mode of operation, function, or effect; (2) the inventions do not overlap in

scope, i.e., are mutually exclusive; and (3) the inventions as claimed are not obvious variants.

See MPEP § 806.05(j). In the instant case, the inventions as claimed have a materially different

structure and function. Each of the following sequences, SEQ ID NO:6-21, is a unique amino

acid sequence, requiring a unique search of the prior art. Searching all of the sequences in a

single patent application would provide an undue search burden on the examiner and the

USPTO's resources because of the non-coextensive nature of these searches. Furthermore,

although each of the sequences represents a putative human transporter protein, each member

of that class has unique and diverse functional features. Therefore, the only common feature of the recited SEQ ID NOs is a general secondary structure resemblance, which is not a basis

upon which to base a search and examination of the claims.

'

Restriction for examination purposes as indicated is proper because all these inventions

listed in this action are independent or distinct for the reasons given above and there would be a

serious search and examination burden if restriction were not required because one or more of

the following reasons apply:

(a) the inventions have acquired a separate status in the art in view of their different

classification;

(b) the inventions have acquired a separate status in the art due to their recognized

divergent subject matter;

Application/Control Number: 10/644,703

Art Unit: 1647

(c) the inventions require a different field of search (for example, searching different classes/subclasses or electronic resources, or employing different search queries):

- (d) the prior art applicable to one invention would not likely be applicable to another invention:
- (e) the inventions are likely to raise different non-prior art issues under 35 U.S.C. 101 and/or 35 U.S.C. 112, first paragraph.

Applicant is advised that the reply to this requirement to be complete <u>must</u> include (i) an election of a invention to be examined even though the requirement may be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse. Traversal must be presented at the time of election in order to be considered timely. Failure to timely traverse the requirement will result in the loss of right to petition under 37 CFR 1.144. If claims are added after the election, applicant must indicate which of these claims are readable on the elected invention.

If claims are added after the election, applicant must indicate which of these claims are readable upon the elected invention. Should applicant traverse on the ground that the inventions are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Application/Control Number: 10/644,703

Art Unit: 1647

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

### Information

Any inquiry concerning this communication or earlier communications from the examiner should be directed to IAN DANG whose telephone number is (571)272-5014. The examiner can normally be reached on Monday-Friday from 9am to 5pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Manjunath Rao can be reached on (571) 272-0939. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 868-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (in USA OR CANADA) or 571-272-1000.

lan Dang Patent Examiner Art Unit 1647 February 28, 2008

/Manjunath N. Rao, / Supervisory Patent Examiner, Art Unit 1647